ADDED
As of February 27, 2026, there were 67,368,052 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stock outstanding.
Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements concerning: our future financial results and liquidity; our business strategy, position and operations; and expected sales trends, opportunities, market position and growth.
Table of C o ntents SUMMARY OF PRINCIPAL RISK FACTORS We are subject to several risks, including risks that may prevent us from achieving our business objectives or that may adversely affect our business, results of operations, financial condition, and cash flows.
Risk Factors , including the following principal risks: our 2025 Credit Agreement contains financial and operating restrictions that could limit our access to credit.
Our portfolio of products is comprised of five patient-focused areas, grouped into three businesses based on clinical use: (i) Pain Treatments PRP ( Pain Treatments ), (ii) Surgical Solutions and (iii) Restorative Therapies.
Pain Treatments , consisting of: Knee Osteoarthritis ( KOA ) : Our product portfolio includes a range of intra-articular, hyaluronic acid ( HA ) injections that help relieve patient discomfort and improve quality of life.
In the U.S., we also distribute the XCELL Platelet-Rich Plasma ( PRP ) system, a technology that is synergistic with our existing physician call points, as many surgeons who use HA also use PRP.
Surgical Solutions , consisting of: Ultrasonics: Our Ultrasonics business offers precision bone resection for patients with degenerative spine conditions and spinal deformities.
Restorative Therapies , consisting of: Fracture Care: We provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods.
clinical fracture care indications to address the healing of additional fresh fractures, especially for high-risk patients.
REMOVED
As of February 27, 2025, there were 66,156,868 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stock outstanding.
Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements concerning our future financial results and liquidity; the impact of our recently divested Advanced Rehabilitation Business on our financial condition and operations; our business strategy, position and operations; and expected sales trends, opportunities, market position and growth.
Risk Factors , including the following principal risks: our Amended 2019 Credit Agreement contains financial and operating restrictions that may limit our access to credit.
We do not control the intellectual property rights covering these technologies and any loss of our rights to these technologies or the rights licensed to us could prevent us from selling our products; and our principal asset is our interest in BV LLC, and, accordingly, we depend on distributions from BV LLC to pay our taxes and expenses, including payments under the Tax Receivable Agreement.
BV LLC s ability to make such distributions may be subject to various limitations and restrictions.
Our portfolio of products is comprised of five patient-focused areas, grouped into three businesses based on clinical use: (i) Pain Treatments, (ii) Surgical Solutions and (iii) Restorative Therapies.
Pain Treatments, comprised of: Knee Osteoarthritis ( KOA ) area : Our product portfolio includes a range of intra-articular, hyaluronic acid ( HA ) injections that help relieve patient discomfort and improve quality of life.
Surgical Solutions, comprised of: Ultrasonics: Our Ultrasonics business offers precision bone resection for patients with degenerative spine conditions and spinal deformities.
Restorative Therapies, comprised of: Fracture Care: We provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods.
We plan to expand our United States clinical indications to address the healing of fresh fractures, especially for high-risk patients.